The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Vera Therapeutics said Tuesday that its recently approved drug Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in patients with a chronic ...
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients ...
Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly ...
Fintel reports that on September 8, 2026, WestPark Capital initiated coverage of Akebia Therapeutics (NASDAQCM:AKBA) with a Buy recommendation. Akebia Therapeutics, Inc. is a United States-based ...
Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.
R1 Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, has launched with an oversubscribed $77.5 million Series A financing to advance a first-in-class treatment for ...
Unicycive Therapeutics pursues late-stage nephrology drug candidates while trading as a micro-cap biotech on Nasdaq. With no fresh market-moving news today, the spotlight shifts to its long-term ...
Lorundrostat led to significant reductions in systolic blood pressure and UACR in CKD patients. Adverse events were low, with 3% discontinuing during lorundrostat vs. 2% on placebo. A new wave of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results